922 related articles for article (PubMed ID: 33523540)
1. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
Jianguo L; Zhixuan Z; Rong L; Xiaodong S
Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
Trantham T; Auten J; Muluneh B; Van Deventer H
J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
Sin JH; Zangardi ML
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
[TBL] [Abstract][Full Text] [Related]
5. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib.
Fuchs A; Orth HM; Germing U; Kondakci M; Holtfreter M; Feldt T; Jensen BE; Häussinger D
Int J Infect Dis; 2020 Nov; 100():382-385. PubMed ID: 32777582
[TBL] [Abstract][Full Text] [Related]
6. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J
Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732
[TBL] [Abstract][Full Text] [Related]
7. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
[TBL] [Abstract][Full Text] [Related]
9. Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report.
Meazza Prina M; Martini F; Bracchi F; Di Mauro D; Fargnoli A; Motta M; Giussani C; Gobbin G; Taverna M; D'Alessio A
BMC Infect Dis; 2021 Aug; 21(1):811. PubMed ID: 34388982
[TBL] [Abstract][Full Text] [Related]
10. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
11. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
[TBL] [Abstract][Full Text] [Related]
13. Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH.
Wang H; Gu J; Liang X; Mao X; Wang Z; Huang W
Semin Hematol; 2020 Jan; 57(1):26-30. PubMed ID: 32690141
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.
Boonstra PS; Ahmed A; Merrill SA; Wilcox RA
Am J Hematol; 2021 Apr; 96(4):E103-E105. PubMed ID: 33428805
[No Abstract] [Full Text] [Related]
16. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
[TBL] [Abstract][Full Text] [Related]
17. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
[TBL] [Abstract][Full Text] [Related]
18. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer.
Portsmore S; Tran Nguyen TN; Beacham E; Neelakantan P
Br J Haematol; 2020 Aug; 190(4):525-528. PubMed ID: 32584421
[No Abstract] [Full Text] [Related]
19. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
[TBL] [Abstract][Full Text] [Related]
20. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Yongzhi X
Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]